Loading…
PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer
Objectives To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long‐term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy. Methods In a retrospective analysis of 77 men treated by ra...
Saved in:
| Published in: | International journal of urology 2014-12, Vol.21 (12), p.1209-1214 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5231-f3c53de5ef960b473f78523fdc5496d0c2c7f1571aad7c31d69754ddd3392a433 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5231-f3c53de5ef960b473f78523fdc5496d0c2c7f1571aad7c31d69754ddd3392a433 |
| container_end_page | 1214 |
| container_issue | 12 |
| container_start_page | 1209 |
| container_title | International journal of urology |
| container_volume | 21 |
| creator | Mithal, Prabhakar Allott, Emma Gerber, Leah Reid, Julia Welbourn, William Tikishvili, Eliso Park, Jimmy Younus, Adib Sangale, Zaina Lanchbury, Jerry S Stone, Steven Freedland, Stephen J |
| description | Objectives
To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long‐term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy.
Methods
In a retrospective analysis of 77 men treated by radical prostatectomy who underwent diagnostic biopsy between 1992–2006, biopsy samples were stained for PTEN expression by the PREZEON assay with >10% staining reported as positive. Cox proportional hazards and log–rank models were used to assess the correlation between PTEN loss and clinical outcomes.
Results
During a median follow‐up period after radical prostatectomy of 8.8 years, 39 men (51%) developed biochemical recurrence, four (5%) had castration‐resistant prostate cancer, two (3%) had metastasis and two (3%) died from prostate cancer. PTEN loss was not significantly associated with biochemical recurrence (hazard ratio 2.1, 95% confidence interval 0.9–5.1, P = 0.10), but significantly predicted increased risk of castration‐resistant prostate cancer, metastasis and prostate cancer‐specific mortality (all log–rank, P |
| doi_str_mv | 10.1111/iju.12571 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1629958622</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1629958622</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5231-f3c53de5ef960b473f78523fdc5496d0c2c7f1571aad7c31d69754ddd3392a433</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqWw4AeQl7BI60cc10uoSmlVykOtWFqu7UguSRPiRNC_x_S1YzazmHPvzFwArjHq4lA9t2q6mDCOT0AbxzGJCIrJKWgjgUXUx5y0wIX3K4QwJbh_DlqEISEwFm3w_DofzmBWeA_dGi5dUfoNrJ33jYVlZY3TtYdlUVRQZ27ttMpg0dS6yO1WUFaFr1VtoVZrbatLcJaqzNurfe-AxeNwPniKpi-j8eB-GmlGKI5Sqhk1ltlUJGgZc5ryfhikRrNYJAZponmKwz9KGa4pNongLDbGUCqIiintgNudb9j_1Vhfy9x5bbNMrW3ReIkTIgTrJ4QE9G6H6nCqr2wqy8rlqtpIjORfejKkJ7fpBfZmb9ssc2uO5CGuAPR2wLfL7OZ_JzmeLA6W0U7hfG1_jgpVfcqEU87kx2wk52j-_sYnD3JCfwHQWYgR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1629958622</pqid></control><display><type>article</type><title>PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Mithal, Prabhakar ; Allott, Emma ; Gerber, Leah ; Reid, Julia ; Welbourn, William ; Tikishvili, Eliso ; Park, Jimmy ; Younus, Adib ; Sangale, Zaina ; Lanchbury, Jerry S ; Stone, Steven ; Freedland, Stephen J</creator><creatorcontrib>Mithal, Prabhakar ; Allott, Emma ; Gerber, Leah ; Reid, Julia ; Welbourn, William ; Tikishvili, Eliso ; Park, Jimmy ; Younus, Adib ; Sangale, Zaina ; Lanchbury, Jerry S ; Stone, Steven ; Freedland, Stephen J</creatorcontrib><description>Objectives
To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long‐term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy.
Methods
In a retrospective analysis of 77 men treated by radical prostatectomy who underwent diagnostic biopsy between 1992–2006, biopsy samples were stained for PTEN expression by the PREZEON assay with >10% staining reported as positive. Cox proportional hazards and log–rank models were used to assess the correlation between PTEN loss and clinical outcomes.
Results
During a median follow‐up period after radical prostatectomy of 8.8 years, 39 men (51%) developed biochemical recurrence, four (5%) had castration‐resistant prostate cancer, two (3%) had metastasis and two (3%) died from prostate cancer. PTEN loss was not significantly associated with biochemical recurrence (hazard ratio 2.1, 95% confidence interval 0.9–5.1, P = 0.10), but significantly predicted increased risk of castration‐resistant prostate cancer, metastasis and prostate cancer‐specific mortality (all log–rank, P < 0.0001), and time from androgen deprivation therapy to castration‐resistant prostate cancer (log–rank, P = 0.003). No patient without PTEN loss developed metastases or died from prostate cancer.
Conclusions
PTEN loss at the time of biopsy seems to predict time to development of metastasis, prostate cancer‐specific mortality and, for the first time, castration‐resistant prostate cancer and response to androgen deprivation therapy after radical prostatectomy. If confirmed by larger studies, this would support the use of PTEN loss as an early marker of aggressive prostate cancer.</description><identifier>ISSN: 0919-8172</identifier><identifier>EISSN: 1442-2042</identifier><identifier>DOI: 10.1111/iju.12571</identifier><identifier>PMID: 25099119</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>biochemical recurrence ; Biomarkers, Tumor - analysis ; Biopsy - methods ; castration-resistant prostate cancer ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; North Carolina - epidemiology ; Prognosis ; prostate cancer ; prostate cancer-specific mortality ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - mortality ; PTEN ; PTEN Phosphohydrolase - analysis ; Retrospective Studies ; Survival Rate - trends ; Time Factors</subject><ispartof>International journal of urology, 2014-12, Vol.21 (12), p.1209-1214</ispartof><rights>2014 The Japanese Urological Association</rights><rights>2014 The Japanese Urological Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5231-f3c53de5ef960b473f78523fdc5496d0c2c7f1571aad7c31d69754ddd3392a433</citedby><cites>FETCH-LOGICAL-c5231-f3c53de5ef960b473f78523fdc5496d0c2c7f1571aad7c31d69754ddd3392a433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25099119$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mithal, Prabhakar</creatorcontrib><creatorcontrib>Allott, Emma</creatorcontrib><creatorcontrib>Gerber, Leah</creatorcontrib><creatorcontrib>Reid, Julia</creatorcontrib><creatorcontrib>Welbourn, William</creatorcontrib><creatorcontrib>Tikishvili, Eliso</creatorcontrib><creatorcontrib>Park, Jimmy</creatorcontrib><creatorcontrib>Younus, Adib</creatorcontrib><creatorcontrib>Sangale, Zaina</creatorcontrib><creatorcontrib>Lanchbury, Jerry S</creatorcontrib><creatorcontrib>Stone, Steven</creatorcontrib><creatorcontrib>Freedland, Stephen J</creatorcontrib><title>PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer</title><title>International journal of urology</title><addtitle>Int J Urol</addtitle><description>Objectives
To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long‐term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy.
Methods
In a retrospective analysis of 77 men treated by radical prostatectomy who underwent diagnostic biopsy between 1992–2006, biopsy samples were stained for PTEN expression by the PREZEON assay with >10% staining reported as positive. Cox proportional hazards and log–rank models were used to assess the correlation between PTEN loss and clinical outcomes.
Results
During a median follow‐up period after radical prostatectomy of 8.8 years, 39 men (51%) developed biochemical recurrence, four (5%) had castration‐resistant prostate cancer, two (3%) had metastasis and two (3%) died from prostate cancer. PTEN loss was not significantly associated with biochemical recurrence (hazard ratio 2.1, 95% confidence interval 0.9–5.1, P = 0.10), but significantly predicted increased risk of castration‐resistant prostate cancer, metastasis and prostate cancer‐specific mortality (all log–rank, P < 0.0001), and time from androgen deprivation therapy to castration‐resistant prostate cancer (log–rank, P = 0.003). No patient without PTEN loss developed metastases or died from prostate cancer.
Conclusions
PTEN loss at the time of biopsy seems to predict time to development of metastasis, prostate cancer‐specific mortality and, for the first time, castration‐resistant prostate cancer and response to androgen deprivation therapy after radical prostatectomy. If confirmed by larger studies, this would support the use of PTEN loss as an early marker of aggressive prostate cancer.</description><subject>biochemical recurrence</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biopsy - methods</subject><subject>castration-resistant prostate cancer</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>North Carolina - epidemiology</subject><subject>Prognosis</subject><subject>prostate cancer</subject><subject>prostate cancer-specific mortality</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - mortality</subject><subject>PTEN</subject><subject>PTEN Phosphohydrolase - analysis</subject><subject>Retrospective Studies</subject><subject>Survival Rate - trends</subject><subject>Time Factors</subject><issn>0919-8172</issn><issn>1442-2042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp1kMtOwzAQRS0EoqWw4AeQl7BI60cc10uoSmlVykOtWFqu7UguSRPiRNC_x_S1YzazmHPvzFwArjHq4lA9t2q6mDCOT0AbxzGJCIrJKWgjgUXUx5y0wIX3K4QwJbh_DlqEISEwFm3w_DofzmBWeA_dGi5dUfoNrJ33jYVlZY3TtYdlUVRQZ27ttMpg0dS6yO1WUFaFr1VtoVZrbatLcJaqzNurfe-AxeNwPniKpi-j8eB-GmlGKI5Sqhk1ltlUJGgZc5ryfhikRrNYJAZponmKwz9KGa4pNongLDbGUCqIiintgNudb9j_1Vhfy9x5bbNMrW3ReIkTIgTrJ4QE9G6H6nCqr2wqy8rlqtpIjORfejKkJ7fpBfZmb9ssc2uO5CGuAPR2wLfL7OZ_JzmeLA6W0U7hfG1_jgpVfcqEU87kx2wk52j-_sYnD3JCfwHQWYgR</recordid><startdate>201412</startdate><enddate>201412</enddate><creator>Mithal, Prabhakar</creator><creator>Allott, Emma</creator><creator>Gerber, Leah</creator><creator>Reid, Julia</creator><creator>Welbourn, William</creator><creator>Tikishvili, Eliso</creator><creator>Park, Jimmy</creator><creator>Younus, Adib</creator><creator>Sangale, Zaina</creator><creator>Lanchbury, Jerry S</creator><creator>Stone, Steven</creator><creator>Freedland, Stephen J</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201412</creationdate><title>PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer</title><author>Mithal, Prabhakar ; Allott, Emma ; Gerber, Leah ; Reid, Julia ; Welbourn, William ; Tikishvili, Eliso ; Park, Jimmy ; Younus, Adib ; Sangale, Zaina ; Lanchbury, Jerry S ; Stone, Steven ; Freedland, Stephen J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5231-f3c53de5ef960b473f78523fdc5496d0c2c7f1571aad7c31d69754ddd3392a433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>biochemical recurrence</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biopsy - methods</topic><topic>castration-resistant prostate cancer</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>North Carolina - epidemiology</topic><topic>Prognosis</topic><topic>prostate cancer</topic><topic>prostate cancer-specific mortality</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - mortality</topic><topic>PTEN</topic><topic>PTEN Phosphohydrolase - analysis</topic><topic>Retrospective Studies</topic><topic>Survival Rate - trends</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mithal, Prabhakar</creatorcontrib><creatorcontrib>Allott, Emma</creatorcontrib><creatorcontrib>Gerber, Leah</creatorcontrib><creatorcontrib>Reid, Julia</creatorcontrib><creatorcontrib>Welbourn, William</creatorcontrib><creatorcontrib>Tikishvili, Eliso</creatorcontrib><creatorcontrib>Park, Jimmy</creatorcontrib><creatorcontrib>Younus, Adib</creatorcontrib><creatorcontrib>Sangale, Zaina</creatorcontrib><creatorcontrib>Lanchbury, Jerry S</creatorcontrib><creatorcontrib>Stone, Steven</creatorcontrib><creatorcontrib>Freedland, Stephen J</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mithal, Prabhakar</au><au>Allott, Emma</au><au>Gerber, Leah</au><au>Reid, Julia</au><au>Welbourn, William</au><au>Tikishvili, Eliso</au><au>Park, Jimmy</au><au>Younus, Adib</au><au>Sangale, Zaina</au><au>Lanchbury, Jerry S</au><au>Stone, Steven</au><au>Freedland, Stephen J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer</atitle><jtitle>International journal of urology</jtitle><addtitle>Int J Urol</addtitle><date>2014-12</date><risdate>2014</risdate><volume>21</volume><issue>12</issue><spage>1209</spage><epage>1214</epage><pages>1209-1214</pages><issn>0919-8172</issn><eissn>1442-2042</eissn><abstract>Objectives
To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long‐term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy.
Methods
In a retrospective analysis of 77 men treated by radical prostatectomy who underwent diagnostic biopsy between 1992–2006, biopsy samples were stained for PTEN expression by the PREZEON assay with >10% staining reported as positive. Cox proportional hazards and log–rank models were used to assess the correlation between PTEN loss and clinical outcomes.
Results
During a median follow‐up period after radical prostatectomy of 8.8 years, 39 men (51%) developed biochemical recurrence, four (5%) had castration‐resistant prostate cancer, two (3%) had metastasis and two (3%) died from prostate cancer. PTEN loss was not significantly associated with biochemical recurrence (hazard ratio 2.1, 95% confidence interval 0.9–5.1, P = 0.10), but significantly predicted increased risk of castration‐resistant prostate cancer, metastasis and prostate cancer‐specific mortality (all log–rank, P < 0.0001), and time from androgen deprivation therapy to castration‐resistant prostate cancer (log–rank, P = 0.003). No patient without PTEN loss developed metastases or died from prostate cancer.
Conclusions
PTEN loss at the time of biopsy seems to predict time to development of metastasis, prostate cancer‐specific mortality and, for the first time, castration‐resistant prostate cancer and response to androgen deprivation therapy after radical prostatectomy. If confirmed by larger studies, this would support the use of PTEN loss as an early marker of aggressive prostate cancer.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>25099119</pmid><doi>10.1111/iju.12571</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0919-8172 |
| ispartof | International journal of urology, 2014-12, Vol.21 (12), p.1209-1214 |
| issn | 0919-8172 1442-2042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1629958622 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | biochemical recurrence Biomarkers, Tumor - analysis Biopsy - methods castration-resistant prostate cancer Follow-Up Studies Humans Male Middle Aged North Carolina - epidemiology Prognosis prostate cancer prostate cancer-specific mortality Prostatic Neoplasms - diagnosis Prostatic Neoplasms - metabolism Prostatic Neoplasms - mortality PTEN PTEN Phosphohydrolase - analysis Retrospective Studies Survival Rate - trends Time Factors |
| title | PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T04%3A13%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PTEN%20loss%20in%20biopsy%20tissue%20predicts%20poor%20clinical%20outcomes%20in%20prostate%20cancer&rft.jtitle=International%20journal%20of%20urology&rft.au=Mithal,%20Prabhakar&rft.date=2014-12&rft.volume=21&rft.issue=12&rft.spage=1209&rft.epage=1214&rft.pages=1209-1214&rft.issn=0919-8172&rft.eissn=1442-2042&rft_id=info:doi/10.1111/iju.12571&rft_dat=%3Cproquest_cross%3E1629958622%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5231-f3c53de5ef960b473f78523fdc5496d0c2c7f1571aad7c31d69754ddd3392a433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1629958622&rft_id=info:pmid/25099119&rfr_iscdi=true |